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 Figure: The excess risk of patient-reported urinary incontinence 
according to the mean dose model based on absorbed dose (solid 
black) and fractionation-corrected dose into equivalent 2-Gy fractions 
using the Linear-quadratic model with a/b=3 for late effects (solid 
grey). Dotted lines indicate 68% confidence intervals. 
Conclusions: Efforts to maintain the mean absorbed urinary bladder 
dose below 29 Gy (mean fractionation-corrected dose of 22 Gy3) in 
prostate-cancer treatments with EBRT may keep the prevalence of 
patient-reported urinary incontinence below 10%. Both dose 
representations provide similar results for the clinically relevant range 
of dose values. 
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Purpose/Objective: In carbon ion radiotherapy, the increased relative 
biological effectiveness (RBE) has to be modeled to arrive at the 
biologically effective dose. In this study, the RBE of carbon ions was 
measured in the spinal cord and the results were compared to 
predictions of the local effect model (LEM) as well as to clinical data 
on normal tissue reactions. 
Materials and Methods: The cranial part of the spinal cord of rats was 
irradiated with 1, 2, 6 or 18 fractions (Fx) of photons or carbon ions, 
respectively [1]. Carbon ion irradiations were performed in the 
plateau region (13 keV/mm) or in the middle of a 1 cm spread-out 
Bragg peak (SOBP, 125 keV/mm). Biological endpoint was the onset of 
paresis grade II within 10 months after irradiation. Dose response 
curves were measured and RBEs were calculated based on D50 (dose at 
50% complication probability). In addition α/β-values were 
determined. 
Results: The RBE-values were 1.44±0.08, 1.37±0.05, 1.33±0.02 and 
1.42±0.02 for the plateau- and 1.77±0.06, 2.17±0.06, 2.97±0.05, and 
5.04±0.08 for the peak-irradiations (1, 2, 6, and 18 Fx, respectively). 
The respective predictions by the clinically applied local effect model 
(LEM I) were 1.14, 1.19, 1.37, and 1.72 for the plateau- and 1.28, 
1.61, 2.35, and 3.80 for the peak irradiations, respectively. The α/β-
values were 2.8±0.4 Gy for photons, 2.1±0.4 Gy for the plateau and 
37.0±5.3 Gy for the peak-irradiations, respectively. 
  
Conclusions: Carbon ion irradiations of the spinal cord are 
significantly more effective in the Bragg-peak than in the plateau 
region. A significant fractionation effect was found only for the 
plateau. The clinically applied LEM-version correctly describes the 
main features although it generally underestimated the RBE in the 
Bragg-peak by about 25% (fig. 1). In contrast, a retrospective clinical 
study determined the biologically equivalent tolerance dose for 5% 
probability of MRI-detected temporal lobe reactions (D5) to be 
68.8±3.3 GyE [2]. This value complies well with clinical experience 
from photon therapy and hence, there is no indication for a significant 
underestimation of the RBE in patients. Meanwhile, improved versions 
of the LEM (LEM II-IV) are available [3,4], which show good agreement 
with the measured RBE-values for the peak region. To clarify the 
relation between experimental, clinical and calculated RBEs, the 
clinical data have to be reanalyzed using LEM IV. Further work is 
ongoing to systematically determine RBE and α/β-values at several 
positions in an extended SOBP corresponding to different LET-values. 
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Purpose/Objective: Post radiation therapy (RT) chronic otitis media 
(COM) has been implicated with incidence of sensory neural hearing 
loss (SNHL) in head & neck cancer (HNCa) patients. The goal of this 
study is to examine the association and evaluate the effect of post-RT 
COM on the dose parameters associated with post-RT SNHL in head 
and neck cancer (HNCa) patients receiving RT ± chemotherapy 
(chemo) using logistic modeling. 
Materials and Methods: Radiation oncology and otolaryngology 
records of 395 HNCa patients who received RT±Chemo were 
retrospectively reviewed to code incidence of post-RT COM and SNHL 
using air & bone conduction thresholds for high frequency hearing at 4 
kHz. The criteria for SNHL was 10 dB increase in hearing threshold 
with respect to baseline evaluation. Median follow up was 5.7 Years 
(range: 0.5-30 years). Mean doses received by the middle ear and 
cochlea were estimated by treatment plan evaluation and used for 
analysis. A Fisher's exact test used to determine association between 
post-RT COM and SNHL. A logistic function was used to describe the 
dose response for incidence of SNHL for patients treated with RT only 
and those with Chemo+RT. In each group the model was fitted first to 
all patients (including those with post RT COM) treated with the 
specific modality (RT only or RT+Chemo) and then to the subset of the 
patients treated with that modality who did not have occurrence of 
post-RT COM. Maximum likelihood method was used to optimize the 
fit. 
Results: Post-RT COM was observed in 31.5% patients. Fisher's exact 
test indicated that post-RT COM was significant in the incidence of 
SNHL (p <0.001). The estimated TD5 & TD10 for RT Only group were 
34.3 Gy, 41.9 Gy when all the patients were included and those for 
subset of patients without post-RT COM were 37.1 Gy, 44.7 Gy. Those 
for Chemo+RT group were 29.8 Gy, 37.4 Gy when all patients included 
and those for subset of patients without post-RT COM were 38.1 Gy, 
